Chris A. Rallis - Oct 8, 2024 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Chris A Rallis
Stock symbol
FENC
Transactions as of
Oct 8, 2024
Transactions value $
-$6,369
Form type
4
Date filed
10/10/2024, 05:14 PM
Previous filing
Aug 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FENC Common Shares Options Exercise $5K +1.96K +4.08% $2.55 50K Oct 8, 2024 Direct F1
transaction FENC Common Shares Sale -$6.37K -1.41K -2.81% $4.53 48.6K Oct 8, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FENC Common Shares Options Exercise -$5K -1.96K -1% $2.55 195K Oct 8, 2024 Options 1.96K $2.55 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023.
F2 Shares sold to satisfy tax obligation on option exercise.
F3 Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023.